<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01386853</url>
  </required_header>
  <id_info>
    <org_study_id>TATPITA20101005</org_study_id>
    <nct_id>NCT01386853</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients</brief_title>
  <official_title>A 12-week, Randomized, Multicenter, Double-blind, Active-controlled, Non-inferiority Study to Compare the Efficacy and Safety of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tai Tien Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tai Tien Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, randomized, multicenter, double-blind, active-controlled, non-inferiority
      study (TATPITA20101005) to compare the efficacy and safety of pitavastatin (Livalo®) and
      atorvastatin (Lipitor®) in high risk hypercholesterolemic patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of LDL-C</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving LDL-C &lt; 100 mg/dL; the changes of HDL-C, TG, non-HDL-C, Apo A1 and Apo B, fasting plasma glucose, fasting insulin level, insulin resistance by the HOMA-IR, HbA1c, free fatty acid, and ADMA</measure>
    <time_frame>Baseline to 4 weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>Pitavastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pitavastatin</intervention_name>
    <description>2 mg QD</description>
    <arm_group_label>Pitavastatin</arm_group_label>
    <other_name>Livalo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>10 mg QD</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged ≥ 20 years old and &lt; 75 years old.

          -  Patient who was eligible and able to participate in the study and accepts to enter the
             study by signing written informed consent.

          -  Patient with fasting LDL-C &gt; 100 mg/dL. The concentration of LDL-C is obtained from
             laboratory examination.

          -  Patient with at least one of the following description (NCEP ATP III guideline).

          -  Female patient with child-bearing potential must take reliable contraception method(s)
             during the participation of the study.

        Exclusion Criteria:

          -  Patient who has participated in other investigational studies within 3 months.

          -  Patient took medication and natural health foods known to alter blood lipid profiles
             within 4 weeks.

          -  Patient is taking any medication or food that is prohibited by the study.

          -  Patient taking Amiodarone will be excluded from this study (due to long half life of
             this medication).

          -  Patient is diagnosed with type 1 DM or has been using insulin/insulin analog
             medication.

          -  Patient with a history of multiple drug allergies or with a known allergy to HMG-CoA
             reductase inhibitors.

          -  Patient with TG &gt; 400 mg/dL.

          -  Excessive obesity defined as BMI above 35 kg/m2.

          -  Cerebral vascular disease (including cerebrovascular hemorrhage or ischemia, transient
             ischemic attack) diagnosed within 3 months.

          -  Myocardial infarction, heart failure (NYHA class III or IV), gross cardiac enlargement
             (cardiothoracic ratio &gt; 0.5), significant heart block or cardiac arrhythmias within 3
             months; history of uncontrolled complex ventricular arrhythmias, uncontrolled atrial
             fibrillation/flutter or uncontrolled supraventricular tachycardia, pacemaker or
             implantable cardiac device were not eligible for this study.

          -  Patient with advanced renal disorder (Serum creatinine levels ≥ 2 mg/dL and BUN ≥ 25
             mg/dL).

          -  Patient with advanced hepatic disorder (AST or ALT level ≥ 100 IU/L)

          -  Patient with CK level &gt; 5 × ULRR at any time point between Visit 1 and Visit 2.

          -  Patient with poorly controlled diabetes mellitus (HbA1c &gt; 9.0%) or patient with severe
             hypertension (&gt; 180 mmHg for systolic or &gt; 120 mmHg in diastolic blood pressure).

          -  Patient with hypothyroidism, hereditary muscular disorders, family history of the
             above or history of drug-induced myopathy.

          -  Patient has significant alcohol consumption (&gt; 65 mL pure alcohol) within 48 hours
             before Visit 2.

          -  Any major surgery within 3 months prior to Visit 2.

          -  Female patient who is lactating, being pregnant or plans to become pregnant.

          -  Patient with conditions judged by the investigator as unsuitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaw-Wen Chen, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jasmine Chao</last_name>
    <phone>+886-27423012</phone>
    <email>jasmine@tanabe.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Chang-hua</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Chien-Hsun Hsia, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lee-Shin Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ping-Yen Liu, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Po-Sheng Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ju-Yi Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei-Ting Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yen-Wen Liu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Han Lee, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei-Chuan Tsai, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Heng Li, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Chan Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shih-Hung Chan, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting-Hsing Chao, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-LinKou</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ming-Shien Wen, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kuo-Chun Hung, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>I-Chang Hsieh, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chao-Yung Wang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Chi Chen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kuo-Liong Chien, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Lun Chao, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ta-Chen Su, M.D. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Ju Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tao-Cheng Wu, M.D. Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chin-Chou Huang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liang-Yu Lin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Chung Yu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2011</study_first_submitted>
  <study_first_submitted_qc>June 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2011</study_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Manager</name_title>
    <organization>Development Department</organization>
  </responsible_party>
  <keyword>Hyperlipidemia</keyword>
  <keyword>Pitavastatin</keyword>
  <keyword>Atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

